Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Your InjectCo nurse clinician will review your health history, explain your options, and tell you honestly whether semaglutide is the right next step
The new indication could give Novo Nordisk a boost against rivals in the GLP-1 agonist class, including Eli Lilly, whose dual GIP/GLP-1 agonist Mounjaro (tirzepatide) competes in the diabetes category and is in a phase 3 trial (TREASURE-CKD) looking at a CKD indication in people with obesity, with and without diabetes
How to Choose the Right MedVi Alternative The best alternative depends on what matters most to you
Some of these include: Class of medication: Semaglutide belongs to the class GLP-1 RAs, while Tirzepatide belongs to the class dual GIP/GLP-1 receptor agonists
IGF-1 LR3 is not an approved medicine
US$ 27.83
US$ 23.63
US$ 22.85
US$ 29.19
US$ 26.19
